Published in Cancer J on April 14, 2006
Medical applications and toxicities of gallium compounds. Int J Environ Res Public Health (2010) 1.15
Cancer-associated hypercalcemia treated with intravenous diphosphonates: a survival and prognostic factor analysis. Support Care Cancer (2007) 1.00
Hypercalcemia of Malignancy: An Update on Pathogenesis and Management. N Am J Med Sci (2015) 0.90
Hypercalcemia of malignancy and new treatment options. Ther Clin Risk Manag (2015) 0.85
Endocrine and metabolic emergencies: hypercalcaemia. Ther Adv Endocrinol Metab (2010) 0.82
An Interesting Case of Life-Threatening Hypercalcemia Secondary to Atypical Parathyroid Adenoma versus Parathyroid Carcinoma. Case Rep Med (2014) 0.81
Malignancy associated hypercalcaemia-responsiveness to IV bisphosphonates and prognosis in a palliative population. Support Care Cancer (2015) 0.76
Hypercalcemia of malignancy remains a clinically relevant problem. Cancer J (2006) 0.75
Cancer-associated hypercalcemia: validation of a bedside prognostic score. Support Care Cancer (2009) 0.75
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol (2005) 7.12
Retracted Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol (2007) 3.67
Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol (2004) 3.40
Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res (2003) 3.10
Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol (2005) 2.85
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood (2003) 2.82
Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood (2002) 2.48
Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood (2008) 1.98
Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin Cancer Res (2003) 1.84
Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood (2011) 1.71
A catalyst for change: the European cancer Patient's Bill of Rights. Oncologist (2014) 1.55
Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene (2002) 1.53
Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer (2002) 1.39
Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood (2005) 1.35
Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res (2007) 1.35
Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis. J Immunol (2007) 1.32
Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. J Clin Oncol (2002) 1.27
A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res (2007) 1.26
Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Res Treat (2009) 1.25
Induction of angiogenesis by normal and malignant plasma cells. Blood (2009) 1.22
Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour. Invest New Drugs (2009) 1.20
Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth. Br J Haematol (2007) 1.17
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood (2009) 1.16
Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol (2004) 1.16
Microarray-based understanding of normal and malignant plasma cells. Immunol Rev (2006) 1.12
Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells. Oncogene (2002) 1.05
The NF-κB member p65 controls glutamine metabolism through miR-23a. Int J Biochem Cell Biol (2012) 1.03
Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Invest New Drugs (2005) 1.01
Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cells. Br J Haematol (2009) 1.00
[Role of radiotherapy in recurrent gliomas]. Bull Cancer (2004) 1.00
Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study. Haematologica (2006) 0.99
Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience. J Clin Oncol (2005) 0.95
Optimal management of nasopharyngeal carcinoma. Curr Opin Oncol (2004) 0.90
Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells. Br J Haematol (2009) 0.90
[PI3K-AKT-mTOR pathway inhibitors]. Bull Cancer (2006) 0.89
γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody. Haematologica (2010) 0.89
Increased plasma-immune cytokines throughout the high-dose melphalan-induced lymphodepletion in patients with multiple myeloma: a window for adoptive immunotherapy. J Immunol (2009) 0.89
Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor. J Immunol (2006) 0.87
Use of angiogenesis inhibitors in tumour treatment. Eur J Cancer (2005) 0.86
Phase 2 study of single-agent IV vinflunine as third-line treatment of metastatic breast cancer after failure of anthracycline-/taxane-based chemotherapy. Am J Clin Oncol (2009) 0.85
Controlled Epstein-Barr virus reactivation after allogeneic transplantation is associated with improved survival. Eur J Haematol (2014) 0.85
A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors. Cell Cycle (2011) 0.85
Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors? Ann Intern Med (2005) 0.84
[Use of the functional imaging modalities in radiation therapy treatment planning in patients with glioblastoma]. Bull Cancer (2005) 0.82
gammadelta T lymphocytes count is normal and expandable in peripheral blood of patients with follicular lymphoma, whereas it is decreased in tumor lymph nodes compared with inflammatory lymph nodes. J Immunol (2009) 0.81
Evaluation of antitumor effects of two vine stalk oligomers of resveratrol on a panel of lymphoid and myeloid cell lines: comparison with resveratrol. Life Sci (2007) 0.81
Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma? Oncotarget (2012) 0.80
Basic fibroblast growth factor-2/beta3 integrin expression profile: signature of local progression after chemoradiotherapy for patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2009) 0.80
Early evaluation of targeted drugs using dynamic contrast-enhanced ultrasonography for personalized medicine. Future Oncol (2012) 0.80
QTc monitoring during a phase I study: experience with SR271425. Am J Clin Oncol (2007) 0.79
Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours. Eur J Cancer (2013) 0.78
European French-speaking study from the GEMO group on bone metastases management: a special focus on external beam radiotherapy practice survey. Support Care Cancer (2010) 0.78
Tyrosine kinase inhibition and grey hair. Lancet (2003) 0.78
Retraction--Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol (2011) 0.78
Paclitaxel, epirubicin and cyclophosphamide combination in first-line treatment of metastatic breast cancer: a dose escalation study. Oncology (2004) 0.78
Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with topotecan in patients with advanced malignancies. Invest New Drugs (2006) 0.77
Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples. Invest New Drugs (2013) 0.77
Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors. Ther Clin Risk Manag (2007) 0.76
Locoregional effects of pegylated liposomal doxorubicin (Caelyx) in irradiated area: a phase I-II study in patients with recurrent squamous cell carcinoma of the head and neck. Eur J Cancer (2004) 0.76
Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors. Cancer Chemother Pharmacol (2010) 0.75
Reply to 'Arsenic patent keeps drug for rare cancer out of reach for many'. Nat Med (2007) 0.75
Re: Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst (2003) 0.75
[Overview of epidermal growth factor inhibitors (with the exclusion of ZD1839 and C225)]. Bull Cancer (2003) 0.75
[Therapeutic efficacy of treatments aimed at the EGF receptor]. Bull Cancer (2003) 0.75
[Anti-epidermal growth factor receptor treatment: a new paradigm for conducting therapeutic trials]. Bull Cancer (2003) 0.75
[The multifaceted large stones of the president of the French Cancer Society]. Bull Cancer (2002) 0.75
[Therapeutic monoclonal antibodies in onco-hematology]. Med Sci (Paris) (2009) 0.75
[Oral drugs inhibiting the VEGF pathway]. Bull Cancer (2007) 0.75
[Refining the French system of cost assessment for oncology patients following chemotherapy]. Bull Cancer (2003) 0.75
[Monoclonal antibody therapy for non-Hodgkin's lymphoma]. Rev Prat (2010) 0.75
Preoperative sequential chemotherapy in locally advanced squamous cell carcinoma of the head and neck. Head Neck (2005) 0.75
[Inhibition of angiogenesis by proteins, peptides and "small molecules"]. Onkologie (2005) 0.75
Immunomarker studies of fine-needle cytopuncture cell blocks for tumor response prediction after preoperative chemotherapy and prognosis in operable nonmetastatic primary breast carcinoma. Breast J (2011) 0.75